190 related articles for article (PubMed ID: 20851117)
1. Pharmacological characterization of the cannabinoid CB₁ receptor PET ligand ortholog, [³H]MePPEP.
Suter TM; Chesterfield AK; Bao C; Schaus JM; Krushinski JH; Statnick MA; Felder CC
Eur J Pharmacol; 2010 Dec; 649(1-3):44-50. PubMed ID: 20851117
[TBL] [Abstract][Full Text] [Related]
2. The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.
Yasuno F; Brown AK; Zoghbi SS; Krushinski JH; Chernet E; Tauscher J; Schaus JM; Phebus LA; Chesterfield AK; Felder CC; Gladding RL; Hong J; Halldin C; Pike VW; Innis RB
Neuropsychopharmacology; 2008 Jan; 33(2):259-69. PubMed ID: 17392732
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and molecular characterization of a dorsal root ganglion cell line expressing cannabinoid CB(1) and CB(2) receptors.
Fan Y; Hooker BA; Garrison TR; El-Kouhen OF; Idler KB; Holley-Shanks RR; Meyer MD; Yao BB
Eur J Pharmacol; 2011 Jun; 659(2-3):161-8. PubMed ID: 21458448
[TBL] [Abstract][Full Text] [Related]
6. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
7. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
Burns HD; Van Laere K; Sanabria-Bohórquez S; Hamill TG; Bormans G; Eng WS; Gibson R; Ryan C; Connolly B; Patel S; Krause S; Vanko A; Van Hecken A; Dupont P; De Lepeleire I; Rothenberg P; Stoch SA; Cote J; Hagmann WK; Jewell JP; Lin LS; Liu P; Goulet MT; Gottesdiener K; Wagner JA; de Hoon J; Mortelmans L; Fong TM; Hargreaves RJ
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9800-5. PubMed ID: 17535893
[TBL] [Abstract][Full Text] [Related]
8. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum.
Wang X; Horswill JG; Whalley BJ; Stephens GJ
Mol Pharmacol; 2011 Apr; 79(4):758-67. PubMed ID: 21189269
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography.
Willis PG; Pavlova OA; Chefer SI; Vaupel DB; Mukhin AG; Horti AG
J Med Chem; 2005 Sep; 48(18):5813-22. PubMed ID: 16134948
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging.
Evens N; Muccioli GG; Houbrechts N; Lambert DM; Verbruggen AM; Van Laere K; Bormans GM
Nucl Med Biol; 2009 May; 36(4):455-65. PubMed ID: 19423014
[TBL] [Abstract][Full Text] [Related]
12. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor.
Griffin G; Tao Q; Abood ME
J Pharmacol Exp Ther; 2000 Mar; 292(3):886-94. PubMed ID: 10688601
[TBL] [Abstract][Full Text] [Related]
13. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.
Terry G; Liow JS; Chernet E; Zoghbi SS; Phebus L; Felder CC; Tauscher J; Schaus JM; Pike VW; Halldin C; Innis RB
Neuroimage; 2008 Jul; 41(3):690-8. PubMed ID: 18456516
[TBL] [Abstract][Full Text] [Related]
15. The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurons and negatively regulates neurite growth in vitro.
Vitalis T; Lainé J; Simon A; Roland A; Leterrier C; Lenkei Z
Eur J Neurosci; 2008 Nov; 28(9):1705-18. PubMed ID: 18973587
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.
Terry GE; Hirvonen J; Liow JS; Seneca N; Tauscher JT; Schaus JM; Phebus L; Felder CC; Morse CL; Pike VW; Halldin C; Innis RB
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1499-506. PubMed ID: 20333514
[TBL] [Abstract][Full Text] [Related]
17. Novel sterically hindered cannabinoid CB1 receptor ligands.
Urbani P; Cascio MG; Ramunno A; Bisogno T; Saturnino C; Di Marzo V
Bioorg Med Chem; 2008 Aug; 16(15):7510-5. PubMed ID: 18579386
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
19. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
